Clinical Trial Update: Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluates whether a laboratory test can predict which patients with relapsed, metastatic or unresectable non-small cell lung cancer will respond…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED